
Inflammation as a Treatable Driver of Atherosclerosis, With Peter Libby, MD
Peter Libby, MD, discusses evidence for inflammation as a causal driver of atherosclerosis and what coronary imaging adds to hs-CRP.
Inflammation is now recognized as a central contributor to atherosclerosis rather than a downstream consequence of plaque formation. Evidence from laboratory research, biomarker studies, and large outcomes trials implicates inflammatory pathways at every stage of the disease, from endothelial activation to acute thrombotic events. With an anti-inflammatory therapy now approved for atherosclerotic disease and new imaging tools emerging, clinicians face growing questions about how to measure and target residual inflammatory risk.
Peter Libby, MD, of Brigham and Women’s Hospital and Harvard Medical School, spoke with HCPLive at the American Heart Association (AHA) Scientific Sessions 2026 about the evidence for a causal role of inflammation in atherosclerosis. He also discussed how coronary inflammation imaging may refine cardiovascular risk assessment beyond systemic biomarkers.
Libby described endothelial activation and the recruitment of inflammatory leukocytes to the artery wall as the earliest steps in atherogenesis, followed by a long period of silent progression. After roughly 25 years of experimental work supporting the inflammatory hypothesis, he identified a single outcomes trial as the pivot point for the field.
What Did CANTOS Establish About Inflammation and Cardiovascular Events?
The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) tested canakinumab, a monoclonal antibody targeting interleukin-1β (IL-1β). Libby had studied this pro-inflammatory cytokine in his laboratory for decades. He instigated and co-led the trial with Paul Ridker, MD, MPH, who presented the results at the European Society of Cardiology Congress in 2017.¹
The trial enrolled 10,061 patients with prior myocardial infarction and hs-CRP levels of 2 mg/L or higher, who were followed for a median of 3.7 years.¹ Canakinumab 150 mg reduced the primary composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death by 15% compared with placebo (HR, 0.85; 95% CI, 0.74–0.98; P = .021).¹ Libby noted the size of this reduction was similar to results from contemporaneous outcome trials of PCSK9 inhibitors.
CANTOS also showed a signal for infectious risk, along with fewer cancer deaths, particularly from lung cancer.¹ Because of the oncology findings, the sponsor chose to develop canakinumab for cancer rather than cardiovascular disease. Libby called CANTOS an important proof of concept for anti-inflammatory therapy, though he emphasized the work is far from finished.
He expects a series of trials aimed at finding what he called the “sweet spot,” where anti-inflammatory efficacy is optimized while unwanted effects such as impaired host defense and tumor surveillance are minimized.
Does an Inflammatory View of Atherosclerosis Change Lipid-Focused Care?
Libby rejected the idea of a competition between traditional risk factors and inflammation, calling it a false dichotomy. He described inflammation and immunity as biological pathways through which hypertension, dyslipidemia, atherogenic lipoproteins, smoking, and oxidative stress converge.
“There’s absolutely no competition between traditional risk factors and inflammation,” Libby said. He characterized these pathways as protective mechanisms that turn against the host when they are activated in excess.
Libby said several established therapies may owe part of their benefit to anti-inflammatory activity. He cited the pleiotropic effects of statins, and possibly bempedoic acid, as anti-inflammatory actions distinct from LDL cholesterol lowering. These dual effects may help explain the success of statins in reducing atherosclerotic events.
He drew a similar parallel with incretin mimetics. With these agents, hs-CRP reductions come before substantial weight loss, much as metabolic benefits come before major weight loss after metabolic surgery.
What Can Coronary Inflammation Imaging Add Beyond hs-CRP?
Libby explained hs-CRP performs well in cardiovascular prediction because it integrates inflammation from every source in the body. These sources range from periodontal disease to infected diabetic foot ulcers. They also include bronchitis, cystitis, inflammatory bowel disease, and autoinflammatory rheumatologic conditions.
“But hs-CRP doesn’t report on local inflammation. It’s agnostic as to the source,” he said.
To assess local inflammation, Libby highlighted the fat attenuation index (FAI) score. The score is derived from artificial intelligence analysis of routine coronary computed tomography angiography and reflects inflammation in the perivascular fat surrounding the coronary arteries. In the ORFAN study, published in The Lancet in 2024, the FAI score predicted cardiovascular events in a large population of patients undergoing clinically indicated CT scans.²
Libby said future research should determine whether the FAI score can identify patients with elevated local coronary risk who are candidates for anti-inflammatory therapy. He described using changes in the FAI score as a marker of treatment benefit as purely speculative for now. However, he stressed the field urgently needs intermediate measures like this to support drug development.
Colchicine is now approved by the US Food and Drug Administration (FDA) as an anti-inflammatory therapy for atherosclerotic disease, and many other programs targeting inflammation are underway. Libby said new imaging tools could help refine patient selection and address residual inflammatory risk in patients whose traditional risk factors are well controlled.
References:
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
Chan K, Wahome E, Tsiachristas A, et al. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. Lancet. 2024;403(10444):2606-2618. doi:10.1016/S0140-6736(24)00596-8
Related to this article








